Clinical Trials Browser

Phase 2 × INDUSTRY × Immune Checkpoint Inhibitors × Clear all

NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Phase 2 Terminated

16 enrolled 13 charts

Oligoprogressive

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Phase 2 Recruiting

First-line Advanced NSCLC Patients

NCT05846646 2025-10-20

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Phase 2 Terminated

6 enrolled 7 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04681131 2025-09-25

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Phase 2 Completed

Small Cell Lung Carcinoma

NCT04673942 2024-10-26

BETA-PRIME

Phase 2 Recruiting

Adenoviridae Infections, Chondrosarcoma, Neoplasms, Sarcoma

NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Phase 2 Unknown

Carcinoma, Transitional Cell